FIELD: biotechnology.
SUBSTANCE: immunogenic composition against one or more polysaccharide antigen, peptide antigen or polypeptide antigen comprises at least one antigenic polysaccharide, at least one peptide or polypeptide antigen and at least one complementary affinity molecules pair. At that, the first affinity molecule is associated with at least one antigenic polysaccharide, and the complementary affinity molecule is associated with at least one peptide or polypeptide antigen, wherein the said first affinity molecule binds to the complementary affinity molecule for the compound of peptide or polypeptide antigen and a polysaccharide antigen.
EFFECT: invention allows to induce both humoral and cellular immune responses to one or multiple antigens simultaneously.
20 cl, 40 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
| IMMUNOGENIC COMPOSITIONS | 2018 |
|
RU2791256C2 |
| POLYVALENT PNEUMOCOCCAL VACCINES | 2019 |
|
RU2815390C2 |
| SELF-ASSEMBLY SYNTHETIC PROTEINS | 2014 |
|
RU2801230C2 |
| SELF-ASSEMBLING SYNTHETIC PROTEINS | 2014 |
|
RU2747857C2 |
| VACCINES AND COMPOSITION AGAINST STREPTOCOCCUS PNEUMONIAE | 2012 |
|
RU2623174C2 |
| COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS | 2014 |
|
RU2717306C2 |
| IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS | 2014 |
|
RU2685185C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
| IMMUNE STIMULATING AND VACCINE COMPOSITIONS | 2011 |
|
RU2578420C2 |
